These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1452 related articles for article (PubMed ID: 34732275)
1. SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence. Tatsi EB; Filippatos F; Michos A Epidemiol Infect; 2021 Nov; 149():e237. PubMed ID: 34732275 [TBL] [Abstract][Full Text] [Related]
2. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization. Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA Microbiol Spectr; 2022 Jun; 10(3):e0178921. PubMed ID: 35638818 [TBL] [Abstract][Full Text] [Related]
3. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD Elife; 2020 Oct; 9():. PubMed ID: 33112236 [TBL] [Abstract][Full Text] [Related]
4. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine. Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM Front Immunol; 2021; 12():747830. PubMed ID: 34858404 [TBL] [Abstract][Full Text] [Related]
5. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern. Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895 [TBL] [Abstract][Full Text] [Related]
6. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines. Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287 [TBL] [Abstract][Full Text] [Related]
13. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection. Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290 [TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. Gong W; Parkkila S; Wu X; Aspatwar A Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216 [TBL] [Abstract][Full Text] [Related]
15. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern. Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH Elife; 2022 Feb; 11():. PubMed ID: 35191378 [TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History. Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006 [TBL] [Abstract][Full Text] [Related]
17. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants. Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM Elife; 2022 Aug; 11():. PubMed ID: 36004719 [TBL] [Abstract][Full Text] [Related]
18. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736 [TBL] [Abstract][Full Text] [Related]
19. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination. Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P Front Immunol; 2022; 13():816389. PubMed ID: 35464418 [TBL] [Abstract][Full Text] [Related]